甘精胰岛素联合格列美脲及阿卡波糖治疗2型糖尿病患者24小时动态血糖变化

Blood glucose profile within 24 h in type 2 diabetic patients treated by glargine combined with glimepiride and acarbose

26例继发性磺脲类失效(SFS)的2型糖尿病患者,改用甘精胰岛素加格列美脲及阿卡波糖治疗3个月后与联合治疗前比较,24．h总体血糖达标时段[(19．1±3．6)h vs(2．3±2．1)h]显著延长,24 h平均血糖[(6．8±1．4)mmoL／Lvs(15．2±3．2)mmol／L]、空腹血糖[(5．4±1．3)mmol／Lvs(11．6±5．2) mmol／L]、24h内最高血糖[(10．8±4．2)mmol／Lvs(20．3±5．6)mmoL／L]及HbAIC[(7．7±1．3)％vs(10．8±1．6％)]均有显著下降(均P<0．01)。提示甘精胰岛素联合格列美脲及阿卡波糖能有效改善SFS的2型糖尿病24h血糖控制。

Twenty-six type 2 diabetic patients with secondary failure to sulfonylureas （SFS） were treated by glargine combined with glimepiride and acarbose for 3 months. The data of continuous glucose monitoring system （CGMS） showed that the time of reaching the target blood glucose （BG） was increased from （2.3 ± 2. 1 ） h to （19.1 ±3.6）h, the mean BG value was lowered from （15.2± 3.2）mmol/L to （6.8 ± 1.4）mmol/L, the fasting BG was lowered from （ 11.6 ± 5.2 ） mmol/L to （ 5.4± 1.3 ） retool/L, the peak BG in 24 h was decreased from （20.3 ±5.6） mmol/L to （ 10.8±4.2） mmol/L, and the HbA1c value was lowered from （ 10.8 ±1.6）% to （7.7 ±1.3） % （ all P 〈 0.01 ） , suggesting that 24 BG control is effectively improved in type 2 diabetic patients with SFS by above combined therapy.